HomePeptides › Matrixyl

Matrixyl

Palmitoyl pentapeptide-4, Pal-KTTKS

Tier 3 · Limited Human Data
Class
Collagen-signalling matrikine
Molecular target
TGF-beta pathway; fibroblast collagen synthesis
Sequence / structure
Palmitoyl-Lys-Thr-Thr-Lys-Ser
Evidence tier
Tier 3 — Limited Human Data
Category
Cosmetic & Topical
Emergency card
Signs something is wrong

Any new or unusual symptom after dosing. Because this compound has little or no human safety data, there is no established list of 'expected' effects to reassure you against — treat anything abnormal as a signal.

What to do now

Stop at the first clearly abnormal reaction and reassess. Keep the vial and lot number in case you need to describe what you actually took.

When it is an emergency

Any severe or fast-worsening symptom — difficulty breathing, chest pain, fainting, severe pain — is a 911 call regardless of the compound.

This is not permission or instruction to use this compound. It is harm-reduction information for someone who has already decided to, so that a bad reaction is recognised and treated. When in doubt, get help — embarrassment is survivable.

Biology & mechanism

A subfragment of type I procollagen. The biology is neat: when collagen is damaged, its breakdown fragments act as signals — matrikines — telling fibroblasts to synthesise more. Pal-KTTKS presents that damage signal without any actual damage. The palmitoyl chain is the engineering that matters: it makes the hydrophilic pentapeptide lipophilic enough to traverse the stratum corneum, which is precisely the problem argireline has not solved.

What the research actually shows

Among the better-supported cosmetic peptides. Controlled studies, including some independent of manufacturers, report reductions in wrinkle depth and improvement in skin roughness over 12 weeks. Effects are modest and slow — consistent with a genuine collagen-synthesis mechanism rather than a cosmetic optical trick.

Regulatory status

A cosmetic ingredient; no FDA pre-approval required. Appearance claims only.

Safety signals

Excellent topical safety record. Low irritancy relative to retinoids, which is much of its commercial appeal.

Clinical trial dosing — what the studies actually used

Topical cosmetic use at low percentages; 12-week studies report modest changes in wrinkle depth. Not injected.

Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.

We report study doses, not protocols

Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.

References & further reading

Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.

Important notice Forge Bioenergy publishes scientific reference information only. Nothing on this site is medical advice, a therapeutic claim, or a recommendation to use any substance in humans. Many peptides described here are not approved by the FDA for any use, and several are approved only for narrow indications under prescription. We do not publish dosing, administration, or usage protocols. Consult a licensed physician before making any medical decision.